Slide 1: Agilent Technologies Q2'22 Results Presentation
Agilent Technologies Q2’22 Results Presentation
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q2'22
Agilent Results Q2’22 Scale and leading technology across Analytical Laboratories and Dx & Clinical markets Q2’22 Financial Metrics Q2’22 Highlights • Revenues: $1.61B, +7.3% y/y • Growth was the driven by strength in Pharma and core(1)(2),+5.4% reported (-2.1% FX, continued momentum in Chemical & E
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q2 core revenue performance reflected strength in Instrumentation, Informatics, and Consumables key end markets led by Pharma and Chemical & for Analytical Laboratories Energy. While the China shutdowns impacted all instrument platforms, GC & GCMS were
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Growth in Q2 was again double-digits, with Services demand for services in BioPharma and for our LC- MS platforms being a few of the highlights. Contract revenue growth was robust across the portfolio, and the consistency of the services business
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q2 core revenue growth was driven by another Pathology, Genomics, and Nucleic Acid Manufacturing outstanding performance from NASD, and strong double-digit growth in our genomics business. • Announced the expanded EU CE-IVD marking for its PD-L1 IHC 28-8 pharmD
Slide 7: Growth in a $65B+ Market – Q2'22 Results by End Market
Growth in a $65B+ Market – Q2’22 Results by End Market Continued momentum in Pharma and C&E Analytical Laboratory End Markets Q2’22 revenues: +8% y/y on core(2) basis Pharma & Biotech: Up 13% on continued BioPharma strength in the US and China Chemical & Energy: Up 9% driven by strength in che
Slide 8: Q3'22 and FY22 Guidance and Forward-looking Considerations
Q3’22 and FY22 Guidance and Forward-looking Considerations Based on April 30, 2022 Exchange Rates Q3’22 Guidance (1) FY22 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,625 $1,650 Net Revenue ($M) $6,670 $6,730 Y/Y Core Revenue Growth (2) 7.2% 8.8% Y/Y Core Revenue Growth (2) 8.0